# 2026 Investment Themes: Institutional Signal Framework Analysis

The convergence of AI-driven demand, geopolitical realignment, and policy catalysts has created an unusually fertile environment for thematic investing in 2026. **Twelve themes stand out as investable**, ranked by signal strength and timing: AI infrastructure and defense technology lead with the strongest signal convergence, while robotics and GLP-1s approach critical inflection points with clear near-term catalysts.

This analysis applies an institutional signal framework—patent filings, VC trajectories, policy catalysts, corporate capex patterns, supply chain shifts, and search trends—to identify where smart money is positioned, where capital will migrate, and which bottlenecks command pricing power.

---

## Research methodology

### Theme lifecycle sequence (12-24 month edge)

```
Academic Research (3-5 yrs) → Policy Framework (2-3 yrs) → VC Funding Acceleration (1-2 yrs)
→ Corporate Revenue Inflection (6-12 mo) → Mainstream Recognition
```

**Key insight:** Themes don't emerge suddenly. The 12-24 month window between institutional positioning and mainstream awareness is repeatable.

### Signal scoring framework (100 points)

| Signal Category | Weight | Sources |
|-----------------|--------|---------|
| Search/Interest Trend | 20% | Google Trends "Rising", Exploding Topics |
| VC/Startup Funding | 20% | Crunchbase, PitchBook, TechCrunch |
| Patent Activity | 15% | USPTO PatentsView, filing velocity |
| ETF Fund Flows | 15% | ETF.com, ETFdb.com |
| Academic Research | 10% | arXiv, SSRN, PubMed |
| Corporate Earnings Mentions | 10% | 10-K filings, earnings calls |
| Social Sentiment | 10% | Twitter/X, Reddit, news volume |

**Scoring thresholds:**
- 70+ → Active position research
- 50-69 → Continue tracking
- <50 → Passive monitoring

### Value chain analysis framework

For each theme, map:
- **Tier 1:** Direct beneficiaries (obvious plays, often priced in)
- **Tier 2:** Component/service suppliers (less obvious, better risk/reward)
- **Tier 3:** Raw materials/infrastructure (longest duration plays)
- **Key Bottleneck:** Who controls the constraint? → Pricing power

**Critical insight:** Bottleneck owners command pricing power. Find the constraint.

### Key questions for every thesis

1. Where is this theme in the lifecycle?
2. What's the bottleneck? Who controls it?
3. What's the catalyst and timeline?
4. Where is smart money positioned vs. where will it migrate?
5. What's the valuation gap between obvious plays and enablers?
6. What invalidates this thesis?

---

## Conviction tier 1: Highest signal convergence

### AI infrastructure beyond chips commands unprecedented capital flows

The AI infrastructure thesis has shifted decisively from compute to physical plant constraints. Power, cooling, and networking now determine who can build AI capacity—and when. Hyperscalers committed **$371 billion in 2025 capex** (up 44% YoY), while data center M&A exceeded **$61 billion** across 100+ transactions. The bottleneck migration creates asymmetric opportunity in overlooked infrastructure plays.

**Signal convergence is extraordinarily strong.** Power transformers face 144-210 week lead times, with prices up 77% since 2019. U.S. utility transmission and distribution capex hit **$84.9 billion** in 2025, with over $1 trillion projected through 2029. Liquid cooling startups raised **$1.4 billion** in 2025 alone (Crusoe Energy's $1.4B round), while optical transceiver demand for 800G/1.6T networking grows 60-100% annually with indium phosphide shortages creating a 2x supply gap.

The value chain mapping reveals clear pricing power:

- **Tier 1 (Direct beneficiaries):** Vertiv, ABB, Eaton, Schneider Electric, GE Vernova for power equipment; Coherent, Marvell, Arista for networking
- **Tier 2 (Component suppliers):** Corning for fiber, Prysmian/Nexans for cables, Cleveland-Cliffs for electrical steel
- **Tier 3 (Raw materials):** Copper producers benefit from data center demand adding **2.5 million metric tons** by 2040
- **Key bottleneck:** Large power transformers—80% historically imported, domestic capacity severely constrained

Capital is currently concentrated in hyperscalers and semiconductor names. **Migration trajectory:** Infrastructure enablers (power equipment, cooling systems, grid utilities) remain under-owned relative to AI software exposure. Valuation gaps between AI software (40-60x revenue) and infrastructure enablers (2-4x revenue) are historically wide.

Theme maturity sits at **acceleration phase** with 6-12 months to broader recognition. Catalysts for 2026 include Stargate Phase 2 buildout, NVIDIA GB200 deployment requiring 100+ kW liquid cooling, 1.6T transceiver production ramp, and PJM capacity constraint developments.

**Risk factors:** Community opposition has delayed or cancelled $64 billion in data center projects since 2023; transformer supply chains remain 80% import-dependent; AI capex sustainability faces scrutiny if ROI disappoints.

---

### Defense technology reaches production-scale inflection

Defense technology has transitioned from venture experiment to production-scale reality. **Anduril's $30.5 billion valuation** after a $2.5B Series G, combined with its $1 billion in 2024 revenue (doubled YoY), signals institutional validation. The sector attracted **$3 billion in VC funding** in 2024, up 11% YoY, with Founders Fund deploying a single $1 billion check.

Signal strength across all vectors is exceptional:

- **Policy:** FY2026 defense budget request of $892.6B; Pentagon Replicator program deploying $1B+ across 30+ autonomous systems efforts; $13B allocated to "Golden Dome" missile defense
- **Corporate capex:** Anduril's Arsenal-1 facility ($1B investment, 5M sq ft, production starting July 2026) demonstrates manufacturing commitment
- **Combat validation:** Shield AI's Hivemind software identified 200+ Russian targets in Ukraine; Skydio drones deployed across all military branches

The value chain shows concentration in software/AI integration:

- **Tier 1:** Anduril (Lattice OS platform), Palantir (330% stock appreciation 2024), Shield AI (Hivemind autonomy)
- **Tier 2:** Skydio ($99.8M Army contract), AeroVironment, established primes integrating startup tech
- **Tier 3:** Advanced materials, specialized sensors, AI chip suppliers
- **Key bottleneck:** Autonomous system software integration—proprietary AI platforms command premium valuations

Capital positioning shows venture capital heavily concentrated in leaders (Anduril, Shield AI). **Migration path:** Traditional defense contractors acquiring or partnering with tech-enabled entrants; expect significant M&A. European defense spending surge (€392B in 2025, targeting 5% GDP by 2035) opens international opportunity.

Theme maturity: **Late growth approaching mainstream.** IPO catalysts are building—Anduril and Shield AI both have public market potential in 2026-2027.

**Risk factors:** Budget volatility from continuing resolutions; ITAR export restrictions limit international revenue; prime contractor competition intensifying as Anduril took Microsoft's $22B IVAS contract.

---

## Conviction tier 2: Strong signals with clear catalysts

### GLP-1s and obesity treatment enter Medicare expansion phase

The obesity drug market represents **the largest pharmaceutical opportunity since statins**, with current sales of $62-70B expanding to $95-200B by 2030-2035. More importantly for timing, 2026 brings two transformative catalysts: **Medicare Part D demonstration begins July 2026** and **Lilly's oral orforglipron approval expected H2 2026**.

Signal evidence shows mature, accelerating adoption:

- **Revenue momentum:** Combined Mounjaro/Zepbound sales hit **$19B in first 9 months of 2025**, overtaking Keytruda as world's top-selling drug
- **Policy catalyst:** CMS BALANCE model provides $245/month negotiated pricing (down from $1,000+), covering ~10% of Medicare beneficiaries
- **Supply chain resolution:** "Positive signals" with 2025 ending in balance; CordenPharma committed €900M expansion
- **Pipeline depth:** Retatrutide (28.7% weight loss), MariTide (monthly dosing), orforglipron (oral convenience) all in late-stage trials

Value chain opportunities beyond the duopoly:

- **Tier 1:** Eli Lilly, Novo Nordisk (dominant but increasingly priced in)
- **Tier 2:** CDMOs with peptide expertise—CordenPharma (targeting €1B peptide sales by 2028), Bachem, PolyPeptide
- **Tier 3:** Fill/finish specialists, autoinjector manufacturers, API suppliers
- **Emerging opportunity:** Generic semaglutide entry after March 20, 2026 patent expiration (Mylan/Natco first-to-file)

Capital flow dynamics show institutional ownership concentrated in Lilly and Novo, with **CDMOs and supply chain enablers under-owned** relative to their margin expansion potential. Oral formulation success could expand addressable market 3-4x by removing injection barrier.

Theme maturity: **Approaching mainstream** with 0-12 month catalyst horizon. The Medicare expansion represents the clearest near-term policy catalyst in healthcare.

**Risk factors:** Goldman Sachs lowered 2030 forecast from $130B to $95B on price erosion concerns (7% annual assumption); discontinuation rates of 50-65% within first year; muscle loss concerns driving pipeline toward muscle-sparing formulations.

---

### Nuclear renaissance gains hyperscaler validation

The nuclear energy theme has transformed from environmental controversy to **AI infrastructure necessity**. Hyperscalers signed **10+ GW of nuclear contracts** in 2024-2025—a remarkable reversal. Microsoft's $16B, 20-year PPA with Constellation for Three Mile Island restart signals the mainstreaming of nuclear for data center power.

Signal strength comes primarily from corporate commitments:

- **Hyperscaler deals:** Microsoft-Constellation (835 MW, 2028), Amazon-Talen (1.9 GW through 2042), Google-Kairos (500 MW SMRs by 2035), Meta (1.1 GW Clinton plant + 1-4 GW new build RFP)
- **Policy tailwinds:** "One Big Beautiful Bill" preserved 45U nuclear production credit without phaseout until 2031
- **SMR progress:** TerraPower received NRC construction permit safety evaluation (December 2025); NuScale signed 6 GW program with ENTRA1/TVA
- **Fusion validation:** Commonwealth Fusion raised $863M Series B (August 2025); Helion began commercial plant construction

Value chain separates near-term and long-term opportunities:

- **Tier 1 (Near-term):** Existing nuclear operators—Constellation, Vistra, Talen Energy have operational assets signing premium PPAs
- **Tier 2:** Nuclear services—GE Vernova, BWX Technologies, Westinghouse
- **Tier 3:** Uranium/fuel—Cameco (production cuts bullish for price), Centrus Energy (sole US HALEU producer, $900M DOE contract)
- **Tier 4 (Long-term):** SMR developers—NuScale (only NRC certified), Kairos, X-energy, Oklo

Capital is positioned in existing operators; **migration trajectory points to uranium and HALEU suppliers** given structural deficit (180M lbs demand vs. 130M lbs production). Bank of America targets $135/lb uranium by 2026 (vs. ~$83 current).

Theme maturity: **Split assessment.** Existing plant deals are **near mainstream** (12 months). SMR deployment is **early stage** (2030+ commercial). Fusion remains **pre-commercial** (2030s).

**Risk factors:** SMR cost overruns (NuScale Idaho cancellation precedent); HALEU supply dependent on Russia/China until Centrus scales; construction timelines historically optimistic.

---

### Robotics and physical AI experience funding explosion

Humanoid robotics experienced **unprecedented funding acceleration** in 2025—$3.2 billion invested in humanoid-focused startups alone, exceeding the previous six years combined. Figure AI's $39 billion valuation after a $1B Series C places the sector at venture capital's center of attention.

Signal evidence shows convergence across multiple vectors:

- **VC momentum:** Global robotics funding hit $6B+ in first 7 months of 2025 (Crunchbase)
- **Corporate validation:** Tesla targeting 50,000 Optimus units in 2026; Agility Robotics achieved 100,000+ tote movements at GXO; Boston Dynamics Electric Atlas entering production
- **AI model breakthroughs:** NVIDIA Isaac GR00T N1 (first open humanoid foundation model), Physical Intelligence π0 ($600M funding), Google Gemini Robotics
- **Commercial milestones:** Figure 03 unveiled; 1X NEO home robot launched at $20K; UBTech hit 1,000 unit production milestone

Value chain presents multiple entry points:

- **Tier 1 (AI/Compute):** NVIDIA (Isaac platform, Jetson chips) holds dominant infrastructure position
- **Tier 2 (Robot OEMs):** Figure AI, Tesla Optimus, Agility, Apptronik, Boston Dynamics competing for humanoid market; Symbotic ($22.7B backlog) leads warehouse automation
- **Tier 3 (Components):** Harmonic Drive (precision actuators), Keyence (sensors, extremely profitable), specialty motor manufacturers
- **Critical risk:** China controls ~70% of humanoid robot component supply chain

Capital concentration in humanoid leaders creates bubble risk; **more stable opportunity lies in warehouse automation** (Symbotic turned first profitable year with $2.25B revenue) and industrial robotics (ABB spinoff Q2 2026 could unlock value).

Theme maturity: **Varies significantly.** Industrial robotics mature (590K units/year). Warehouse automation late growth. Humanoid industrial early commercial (2026-2028). Humanoid consumer pre-commercial (2027-2030).

**Risk factors:** Tesla Optimus produced only "hundreds" vs. 5K-10K target; Unitree G1 at $16K disrupts Western pricing; technical barriers in unstructured environments remain significant.

---

### Critical minerals face structural supply crisis

The critical minerals thesis has evolved from speculative commodity play to **strategic national security imperative**. China's export restrictions on antimony (97% drop in shipments), gallium, germanium, and graphite have exposed catastrophic Western supply chain dependence.

Signal evidence shows crisis-level urgency:

- **Antimony:** Prices surged 300%+ to $51,500/ton (record); China export restrictions imposed September 2024
- **Copper:** S&P Global projects **10 million metric ton supply shortfall by 2040**; treatment charges hit $0/ton (unprecedented)
- **Rare earths:** Pentagon invested $400M equity stake in MP Materials (15% ownership); China controls 70% mining, 90% processing
- **Policy response:** US-Australia $8.5B critical minerals framework (October 2025); copper designated US critical mineral (November 2025)

Value chain opportunities cluster around Western supply development:

- **Tier 1 (Copper producers):** Freeport-McMoRan ($4.5B capex in 2027, Bagdad expansion decision H1 2026), BHP, Southern Copper
- **Tier 2 (Rare earth Western producers):** MP Materials (government-backed, Texas magnets 2026), Lynas (first non-China dysprosium production)
- **Tier 3 (Antimony):** Perpetua Resources (only US antimony reserve, $1.8B EXIM support), Nova Minerals ($43.4M DPA grant)
- **Tier 4 (Lithium):** Market transitioning to deficit in 2026 per Morgan Stanley (80,000-ton shortfall projected)

Capital is flowing to government-backed projects; **valuation gaps exist in mid-tier developers** with permitting visibility. Battery recycling (Redwood Materials, American Battery Technology) provides circular economy exposure.

Theme maturity: **Crisis/acceleration phase** for antimony, gallium, germanium. **Scaling** for lithium (surplus-to-deficit). **Constrained mature** for copper.

**Risk factors:** China export control suspension expires November 2026; permitting challenges delayed Resolution Copper; price volatility cuts both ways.

---

## Conviction tier 3: Emerging themes with longer horizons

### Energy storage reaches grid-scale economics

The energy storage market has achieved cost curves that make deployment inevitable. Battery pack prices hit **$108/kWh average in 2025**, with stationary storage at **$70/kWh** (45% decline from 2024)—now the cheapest lithium-ion segment for the first time.

Signal evidence shows deployment acceleration:

- **Deployment scale:** 92 GW/247 GWh projected global deployment in 2025 (+23% YoY); US added 10.9 GW through Q3 2025 (equaling all of 2024)
- **Long-duration breakthrough:** Form Energy's iron-air technology (100-hour duration) entering commercial pilot; $405M Series F, $150M DOE grant
- **Virtual power plants:** Market growing to $16-39B by 2030-2034; Tesla enrolled 100,000+ Powerwalls in VPPs

Value chain maps across technology and application:

- **Tier 1 (System integrators):** Tesla, Fluence, BYD, Sungrow
- **Tier 2 (Cell manufacturers):** CATL, LG Energy, Samsung SDI
- **Tier 3 (LDES developers):** Form Energy (iron-air), ESS Tech (iron flow)
- **Tier 4 (Grid software/VPP):** AutoGrid, Next Kraftwerke, Siemens

**Key risk:** OBBBA reduced IRA storage benefits; FEOC restrictions challenge supply chain compliance.

---

### Space economy achieves commercial profitability

Starlink's **first profitable year in 2024** ($72.7M net profit) validates LEO constellation economics after billions in investment. The sector reaches **$450-650 billion in 2025**, with commercial revenues representing 80% of activity.

Signal evidence shows maturation with defense tailwinds:

- **SpaceX dominance:** 165 missions in 2025; $15-16B revenue; 9+ million Starlink subscribers
- **Defense spending:** Space Force FY2026 request ~$40B (30%+ increase); $25B Golden Dome initial investment
- **Commercial stations:** Vast Haven-1 targeting May 2026 launch (first standalone commercial LEO station)

Value chain stratifies by maturity:

- **Tier 1 (Mature):** SpaceX, Starlink (limited public access)
- **Tier 2 (Public opportunity):** Planet Labs ($736M backlog, +245%), Rocket Lab ($816M defense contract)
- **Tier 3 (Emerging):** Astroscale (debris removal leader), Axiom (orbital data centers)

**2026 catalysts:** Amazon Leo service launch, NASA CLD Phase 2 awards (~$1.5B), Rocket Lab Neutron first flight.

---

### Gene therapy reaches commercial inflection

CASGEVY (the first CRISPR therapy) achieving **110 cell collections in first 9 months of 2025** (double all of 2024) signals commercial traction. More importantly, in vivo gene editing for common diseases shows breakthrough potential.

Signal evidence shows pipeline maturation:

- **Commercial progress:** CASGEVY approved in US, UK, EU; $2.2M per treatment; 65+ authorized treatment centers
- **In vivo breakthrough:** Verve VERVE-102 achieved 53% LDL reduction via single infusion; FDA Fast Track granted; Eli Lilly acquired Verve (June 2025)
- **Manufacturing resolution:** "Capacity is no longer the limiting factor"—expertise is the constraint

Value chain shows concentration in integrated players:

- **Tier 1:** Vertex/CRISPR Therapeutics (CASGEVY), Intellia (hATTR in Phase 3)
- **Tier 2:** CDMOs—Charles River (nAAVigation platform, 55% timeline reduction), Lonza
- **Emerging:** In vivo cardiovascular editing (Verve/Lilly)

**Risk factors:** $2.2M pricing limits addressable market; Verve VERVE-101 was paused; durability uncertainty.

---

### Cybersecurity evolves with AI and quantum threats

Cybersecurity VC funding surged to **$13.97 billion in 2025** (+47% YoY)—the strongest year since 2022's correction. Alphabet's **$32 billion acquisition of Wiz** (largest VC-backed acquisition ever) validates cloud security leadership.

Signal evidence shows regulatory-driven demand:

- **Funding momentum:** ReliaQuest $500M Series G, NinjaOne $500M at $5B valuation
- **Policy catalysts:** CIRCIA final rule (May 2026) mandates 72-hour incident reporting for critical infrastructure
- **Quantum urgency:** NIST post-quantum standards released (August 2024); government migration deadline January 2027 for new systems
- **AI security emerging:** Noma Security $100M Series B, SentinelOne acquired Prompt Security

Value chain evolves toward platform consolidation:

- **Tier 1 (Platforms):** CrowdStrike, Palo Alto Networks, Microsoft
- **Tier 2 (Specialists):** Wiz (cloud), Zscaler (SASE), CyberArk (identity)
- **Tier 3 (Emerging):** Post-quantum cryptography vendors, AI security specialists

**2026 catalysts:** CIRCIA implementation, post-quantum migration acceleration, potential late-stage company IPOs.

---

### Grid modernization becomes mandatory infrastructure spend

Global grid investment hit **$470 billion in 2025** (+16% YoY), with US utilities committing $1.1 trillion through 2029. This isn't discretionary—transformer supply deficits of 30% for power transformers and aging infrastructure (40 million US distribution transformers beyond service life) force investment.

**Signal evidence:** NREL estimates US may need 260% more large transformers by 2050; DOE National Transmission Needs Study calls for 64% capacity expansion by 2040.

**Value chain leaders:** Siemens Energy, Hitachi Energy (both expanding US manufacturing), ABB, Quanta Services.

**Key risk:** Lead times exceeding 2 years for large transformers constrain deployment pace.

---

## Themes requiring extended patience

### Longevity science remains high-risk venture territory

**$8.49 billion invested in 2024** (doubled from 2023) validates institutional interest, but **Unity Biotechnology's liquidation** (September 2025) after failed Phase 2 trials demonstrates execution risk. Altos Labs ($3B funding), Retro Biosciences ($180M seed, targeting $1B Series A), and NewLimit ($130M Series B) represent the frontier.

**Investment horizon:** 5-10+ years to clinical validation. Policy tailwinds building (administration "explicitly pro-longevity") but science remains early.

---

### Agricultural technology faces sector-specific distress

AgTech funding declined 70% from 2022 peak, and vertical farming faces existential crisis—**28+ companies filed bankruptcy or closed in 2024** including Plenty ($1B+ raised) and Bowery ($700M+ raised).

**Selective opportunity exists** in precision agriculture (John Deere's See & Spray used on 5 million acres) and agricultural biologicals ($18.44B market growing 13.7% CAGR). Avoid distressed segments.

---

## Capital flow timing and valuation gaps

The most significant valuation gap exists between **AI infrastructure and AI software**. Cloud security and AI software trade at 20-50x revenue multiples while power equipment manufacturers trade at 2-4x revenue despite capturing the same AI demand vector with higher barriers to entry.

**Smart money positioning** shows:

| Theme | Current institutional focus | Likely migration |
|-------|---------------------------|------------------|
| AI Infrastructure | Hyperscalers, semiconductors | Power equipment, cooling, networking |
| Defense Tech | Palantir, Anduril (private) | European defense, munitions, shipbuilding |
| GLP-1s | Lilly, Novo | CDMOs, generics post-March 2026 |
| Nuclear | Utilities (Constellation, Vistra) | Uranium, HALEU suppliers |
| Robotics | Humanoid leaders | Warehouse automation, components |
| Critical Minerals | Large miners | Mid-tier developers with permits |

---

## Conviction ranking summary

| Rank | Theme | Maturity | Time to catalyst | Key signal |
|------|-------|----------|-----------------|------------|
| 1 | AI Infrastructure | Acceleration | 0-12 months | $371B hyperscaler capex |
| 2 | Defense Technology | Late growth | 0-12 months | $30.5B Anduril valuation |
| 3 | GLP-1s/Obesity | Mainstream | 6 months (Medicare) | $19B 9-month sales |
| 4 | Nuclear (existing) | Mainstream | 0-24 months | 10+ GW hyperscaler deals |
| 5 | Robotics | Early commercial | 12-24 months | $6B+ 2025 funding |
| 6 | Critical Minerals | Crisis/scaling | 12-24 months | 300%+ antimony surge |
| 7 | Energy Storage | Growth | 12-24 months | $70/kWh cost achieved |
| 8 | Space Economy | Growth | 12-24 months | Starlink profitable |
| 9 | Gene Therapy | Early commercial | 24-36 months | 110 CASGEVY collections |
| 10 | Cybersecurity | Growth | 6-12 months | $32B Wiz acquisition |
| 11 | Grid Modernization | Forced spend | 12-36 months | 30% transformer deficit |
| 12 | Nuclear (SMR/fusion) | Pre-commercial | 2028+ | Licensing progress |

---

## Portfolio construction considerations

For investors seeking exposure across themes, the research suggests a barbell approach:

**Near-term catalyst plays (6-12 months):** AI power infrastructure (ABB, Eaton, Vertiv), defense software (Palantir), GLP-1 CDMOs (CordenPharma), existing nuclear operators (Constellation), cybersecurity platforms (CrowdStrike, Palo Alto).

**Structural growth (12-24+ months):** Liquid cooling pure-plays, uranium producers (Cameco, Centrus), warehouse automation (Symbotic), copper producers (Freeport-McMoRan), rare earth processors (MP Materials).

**Venture/early-stage (24+ months):** Humanoid robotics (via NVIDIA infrastructure exposure), SMR developers, long-duration storage (Form Energy), gene therapy CDMOs.

The key insight across themes: **bottleneck owners command pricing power**. Whether transformers in AI infrastructure, HALEU in nuclear, or peptide manufacturing in GLP-1s, the companies controlling constrained supply have asymmetric upside as demand accelerates against fixed capacity.

---

## Research routine

### Weekly

**Monday:**
- Google Trends "Rising" for target sectors
- arXiv/SSRN new submissions
- SEC RSS feeds for tech mentions

**Mid-week:**
- ETF fund flows for thematic activity
- VC deal announcements
- Policy/regulatory news

**Friday:**
- Document new signals
- Score against framework
- Update watchlist

### Monthly

- Full watchlist rescore
- Theme stage reassessment

### Current high-priority research areas

Based on signal strength and near-term catalysts:

1. **AI Power Infrastructure** — Transformers, cooling, grid utilities
2. **Uranium/HALEU** — Supply deficit, hyperscaler demand
3. **GLP-1 Supply Chain** — CDMOs before Medicare expansion
4. **Defense Tech IPOs** — Anduril, Shield AI pipeline
5. **Critical Minerals** — Western supply development plays
6. **Robotics Components** — Actuators, sensors, automation software
